Compare Stocks: SMMT, MRK, LPA, and RVMD

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
LPA Logistic Properties of the Americas	$2.99 +1.7%	$3.22	$2.04 ▼ $6.90	$92.96M	5.38	37,733 shs	8,581 shs
MRK Merck & Co., Inc.	$128.61 +0.2%	$123.98	$77.58 ▼ $135.05	$317.05B	0.19	8.87 million shs	7.35 million shs
RVMD Revolution Medicines	$205.15 +3.7%	$176.66	$34.14 ▼ $205.90	$42.40B	1.39	1.86 million shs	1.67 million shs
SMMT Summit Therapeutics	$13.96 +3.1%	$14.29	$12.25 ▼ $30.05	$10.80B	-1.23	3.72 million shs	2.17 million shs

7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
LPA Logistic Properties of the Americas	+1.70%	+1.70%	-9.67%	-12.06%	-50.41%
MRK Merck & Co., Inc.	+0.26%	-1.44%	+1.99%	+15.60%	+61.95%
RVMD Revolution Medicines	+3.71%	+9.40%	+8.10%	+44.67%	+459.45%
SMMT Summit Therapeutics	+3.10%	+7.22%	-11.03%	-22.79%	-51.05%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
LPA Logistic Properties of the Americas	$2.99 +1.7%	$3.22	$2.04 ▼ $6.90	$92.96M	5.38	37,733 shs	8,581 shs
MRK Merck & Co., Inc.	$128.61 +0.2%	$123.98	$77.58 ▼ $135.05	$317.05B	0.19	8.87 million shs	7.35 million shs
RVMD Revolution Medicines	$205.15 +3.7%	$176.66	$34.14 ▼ $205.90	$42.40B	1.39	1.86 million shs	1.67 million shs
SMMT Summit Therapeutics	$13.96 +3.1%	$14.29	$12.25 ▼ $30.05	$10.80B	-1.23	3.72 million shs	2.17 million shs

7 Best Space Stocks to Own in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
LPA Logistic Properties of the Americas	+1.70%	+1.70%	-9.67%	-12.06%	-50.41%
MRK Merck & Co., Inc.	+0.26%	-1.44%	+1.99%	+15.60%	+61.95%
RVMD Revolution Medicines	+3.71%	+9.40%	+8.10%	+44.67%	+459.45%
SMMT Summit Therapeutics	+3.10%	+7.22%	-11.03%	-22.79%	-51.05%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
LPA Logistic Properties of the Americas	2.00	Hold	$7.50	150.84% Upside
MRK Merck & Co., Inc.	2.65	Moderate Buy	$134.56	4.62% Upside
RVMD Revolution Medicines	2.95	Moderate Buy	$153.05	-25.39% Downside
SMMT Summit Therapeutics	2.44	Hold	$26.15	87.35% Upside

Current Analyst Ratings Breakdown

Latest SMMT, MRK, LPA, and RVMD Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/6/2026	RVMD Revolution Medicines	Evercore Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$230.00
8/6/2026	RVMD Revolution Medicines	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$192.10 ➝ $201.00
8/6/2026	RVMD Revolution Medicines	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$230.00
8/6/2026	RVMD Revolution Medicines	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$182.00 ➝ $203.00
8/6/2026	SMMT Summit Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral
8/6/2026	RVMD Revolution Medicines	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$235.00 ➝ $240.00
8/6/2026	RVMD Revolution Medicines	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$236.00 ➝ $240.00
8/5/2026	MRK Merck & Co., Inc.	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$145.00 ➝ $146.00
7/29/2026	MRK Merck & Co., Inc.	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$140.00 ➝ $150.00
7/24/2026	SMMT Summit Therapeutics	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$15.00
7/24/2026	SMMT Summit Therapeutics	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$45.00 ➝ $38.00

(Data available from 8/8/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
LPA Logistic Properties of the Americas	$50.13M	1.89	$0.37 per share	8.07	$10.27 per share	0.29
MRK Merck & Co., Inc.	$65.01B	4.89	$11.44 per share	11.24	$21.22 per share	6.06
RVMD Revolution Medicines	$11.58M	3,797.22	N/A	N/A	$8.44 per share	24.31
SMMT Summit Therapeutics	N/A	N/A	N/A	N/A	$0.79 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
LPA Logistic Properties of the Americas	$10.50M	N/A	29.90	5.75	N/A	6.31%	1.08%	0.49%	8/12/2026 (Estimated)
MRK Merck & Co., Inc.	$18.25B	$1.25	102.89	13.30	5.53	4.77%	16.05%	6.11%	N/A
RVMD Revolution Medicines	-$1.13B	-$7.07	N/A	N/A	N/A	N/A	-102.61%	-70.72%	N/A
SMMT Summit Therapeutics	-$1.08B	-$1.12	N/A	N/A	N/A	N/A	-168.94%	-141.92%	10/19/2026 (Estimated)

Latest SMMT, MRK, LPA, and RVMD Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2026	Q2 2026	LPA Logistic Properties of the Americas	$0.04	N/A	N/A	N/A	$14.14 million	N/A
8/5/2026	Q2 2026	RVMD Revolution Medicines	-$2.04	-$3.06	-$1.02	-$3.06	$1.77 million	N/A
8/4/2026	Q2 2026	MRK Merck & Co., Inc.	-$0.26	-$0.13	+$0.13	-$0.54	$16.37 billion	$16.61 billion
7/23/2026	Q2 2026	SMMT Summit Therapeutics	-$0.2744	-$0.28	-$0.0056	-$0.28	$0.11 million	N/A
5/14/2026	Q1 2026	LPA Logistic Properties of the Americas	N/A	-$0.25	N/A	-$0.25	N/A	$14.40 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
LPA Logistic Properties of the Americas	N/A	N/A	N/A	N/A	N/A
MRK Merck & Co., Inc.	$3.40	2.64%	+5.75%	272.00%	14 Years
RVMD Revolution Medicines	N/A	N/A	N/A	N/A	N/A
SMMT Summit Therapeutics	N/A	N/A	N/A	N/A	N/A

Latest SMMT, MRK, LPA, and RVMD Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
7/29/2026	MRK Merck & Co., Inc.	quarterly	$0.85	2.61%	9/15/2026	9/15/2026	10/7/2026
5/26/2026	MRK Merck & Co., Inc.	quarterly	$0.85	2.96%	6/15/2026	6/15/2026	7/8/2026

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
LPA Logistic Properties of the Americas	0.93	1.57	1.57
MRK Merck & Co., Inc.	1.02	1.30	1.06
RVMD Revolution Medicines	0.19	6.80	6.80
SMMT Summit Therapeutics	N/A	6.96	6.96

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
LPA Logistic Properties of the Americas	42.71%
MRK Merck & Co., Inc.	76.07%
RVMD Revolution Medicines	94.34%
SMMT Summit Therapeutics	4.61%

Insider Ownership

Company	Insider Ownership
LPA Logistic Properties of the Americas	32.00%
MRK Merck & Co., Inc.	0.17%
RVMD Revolution Medicines	7.60%
SMMT Summit Therapeutics	83.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
LPA Logistic Properties of the Americas	30	31.62 million	21.50 million	N/A
MRK Merck & Co., Inc.	75,000	2.47 billion	2.47 billion	Optionable
RVMD Revolution Medicines	250	214.34 million	196.44 million	Optionable
SMMT Summit Therapeutics	110	797.75 million	131.63 million	Optionable

SMMT, MRK, LPA, and RVMD Headlines

Recent News About These Companies

These New Drugs Could Fuel Fresh Highs for Biotech and Pharma Stocks

August 7 at 1:15 AM | barrons.com

Summit Therapeutics Further Expands Ivonescimab Global Development Program with Phase II/III HARMONi-GU1 Study in 1L Bladder Cancer

August 5 at 12:50 PM | finance.yahoo.com

Jim Cramer Calls Summit Therapeutics A 'Great Spec,' Recommends Buying This Consumer Cyclical Stock

August 4, 2026 | benzinga.com

The Manufacturers Life Insurance Company Has $11.24 Million Stake in Summit Therapeutics PLC $SMMT

August 4, 2026 | marketbeat.com

Summit Therapeutics PLC (NASDAQ:SMMT) Given Consensus Rating of "Hold" by Analysts

August 3, 2026 | americanbankingnews.com

Summit Therapeutics PLC (NASDAQ:SMMT) Receives Average Rating of "Hold" from Analysts

August 3, 2026 | marketbeat.com

Summit Therapeutics: Upgrading To Hold As Critical Approval Decision Approaches

July 31, 2026 | seekingalpha.com

What is HC Wainwright's Forecast for SMMT FY2026 Earnings?

July 31, 2026 | americanbankingnews.com

Analysts Offer Insights on Healthcare Companies: Summit Therapeutics (SMMT) and Argenx Se (ARGX)

July 30, 2026 | theglobeandmail.com

What is HC Wainwright's Estimate for SMMT FY2026 Earnings?

July 29, 2026 | marketbeat.com

Analysts Conflicted on These Healthcare Names: HCA Healthcare (HCA), Summit Therapeutics (SMMT) and Neuphoria Therapeutics (NEUP)

July 29, 2026 | theglobeandmail.com

Summit Therapeutics (NASDAQ:SMMT) Hits New 12-Month Low - Time to Sell?

July 28, 2026 | marketbeat.com

Kuehn Law Encourages Investors of Summit Therapeutics Inc. to Contact Law Firm

July 27, 2026 | prnewswire.com

SMMT Stock Heads For Third Straight Weekly Drop – Analyst Tempers Expectations From Initial Lung Cancer Trial Survival Data

July 24, 2026 | msn.com

Traders Purchase High Volume of Call Options on Summit Therapeutics (NASDAQ:SMMT)

July 24, 2026 | marketbeat.com

Summit Therapeutics (NASDAQ:SMMT) Shares Gap Down After Earnings Miss

July 24, 2026 | marketbeat.com

SMMT's Q2 Loss Wider Than Expected, Ivonescimab Development in Focus

July 24, 2026 | zacks.com

Summit Therapeutics (SMMT) Updates Phase III Survival Data, Is The Stock Still A Bargain?

July 23, 2026 | finance.yahoo.com

Summit Therapeutics Inc. (SMMT) Q2 2026 Earnings Call Transcript

July 23, 2026 | seekingalpha.com

Summit Therapeutics Inc. 2026 Q2 - Results - Earnings Call Presentation

July 23, 2026 | seekingalpha.com

Summit Therapeutics Q2 Earnings Call Highlights

July 23, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

SMMT, MRK, LPA, and RVMD Company Descriptions

Logistic Properties of the Americas NYSEAMERICAN:LPA

$2.99 +0.05 (+1.70%)

Closing price 08/7/2026 04:10 PM Eastern

Extended Trading

$2.98 -0.01 (-0.27%)

As of 08/7/2026 08:00 PM Eastern

Logistic Properties of the Americas develops, builds and operates logistic real estate properties. It operates through the following geographical segments: Colombia, Peru, and Costa Rica. The company is headquartered in Miami, FL.

Merck & Co., Inc. NYSE:MRK

$128.61 +0.24 (+0.19%)

Closing price 08/7/2026 03:59 PM Eastern

Extended Trading

$127.95 -0.66 (-0.51%)

As of 08/7/2026 07:57 PM Eastern

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Revolution Medicines NASDAQ:RVMD

$205.15 +7.34 (+3.71%)

Closing price 08/7/2026 04:00 PM Eastern

Extended Trading

$203.82 -1.33 (-0.65%)

As of 08/7/2026 07:56 PM Eastern

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

Summit Therapeutics NASDAQ:SMMT

$13.96 +0.42 (+3.10%)

Closing price 08/7/2026 04:00 PM Eastern

Extended Trading

$13.97 +0.01 (+0.09%)

As of 08/7/2026 07:55 PM Eastern

Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab, as well as strategic collaboration with The University of Texas MD Anderson Cancer Center for the purpose of accelerating the development of ivonescimab. The company was founded in 2003 and is headquartered in Miami, Florida.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SMMT, MRK, LPA, and RVMD Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SMMT, MRK, LPA, and RVMD Earnings

Compare Dividends

Latest SMMT, MRK, LPA, and RVMD Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SMMT, MRK, LPA, and RVMD Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

SMMT, MRK, LPA, and RVMD Company Descriptions

Logistic Properties of the Americas NYSEAMERICAN:LPA

Merck & Co., Inc. NYSE:MRK

Revolution Medicines NASDAQ:RVMD

Summit Therapeutics NASDAQ:SMMT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SMMT, MRK, LPA, and RVMD Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SMMT, MRK, LPA, and RVMD Earnings

Compare Dividends

Latest SMMT, MRK, LPA, and RVMD Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SMMT, MRK, LPA, and RVMD Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

SMMT, MRK, LPA, and RVMD Company Descriptions

Logistic Properties of the Americas NYSEAMERICAN:LPA

Merck & Co., Inc. NYSE:MRK

Revolution Medicines NASDAQ:RVMD

Summit Therapeutics NASDAQ:SMMT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools